FDA advisers to vote Tuesday on Merck’s COVID-19 pill even as interest has waned

The advisory committee will decide whether the benefits of Merck’s experimental antiviral COVID-19 pill outweigh its risks.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.